Biology Reference
In-Depth Information
now available (Matz et al., 1999). They will allow wider application of GFP for
¯uorescence resonance energy transfer ( FRET ) for the studies of viral protein
interaction with each other and with cellular proteins at di¨erent stages of viral
life cycles. Novel instrumentation for high-throughput cell imaging and ¯uo-
rescence detection will facilitate applications of ¯uorescent proteins in antiviral
drug development.
REFERENCES
Akari H, Arold S, Fukumuri T, Toshiyuki O, Strebel K, Adachi A. 2000. Nef-induced major his-
tocompatibility complex class I down-regulation is functionally dissociated from its virion in-
corporation, enhancement of viral infectivity and CD4 down-regulation. J Virol 74: 2907±2912.
Alexander L, Veazey RS, Czajak S, DeMaria M, Rosenzweig M, Lackner AA, Desrosiers RC,
Sasseville VG. 1999. Recombinant simian immunode®ciency virus expressing green ¯uorescent
protein identi®es infected cells in rhesus monkeys. AIDS Res Hum Retroviruses 15: 11±21.
Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, Baggiolini M, Virelizier
JL, Arenzana-Seisdedos F. 1997. HIV coreceptor downregulation as antiviral principle: SDF-
1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of
HIV replication. J Exp Med 186: 139±146.
Bess JW, Gorelick RJ, Bosche W, Henderson LE, Arthur LO. 1997. Microvesicles are a source of
contaminating cellular proteins found in puri®ed HIV-1 preparations. Virology 230: 134±144.
Boritz E, Gerlach J, Johnson JE, Rose JK. 1999. Replication-competent rhabdoviruses with human
immunode®ciency virus type 1 coats and green ¯uorescent protein: entry by a pH-independent
pathway. J Virol 73: 6937±6945.
BouHamdan M, Kulkosky J, Duan LX, Pomerantz RJ. 2000. Inhibition of HIV-1 replication and
infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment
(SFv): intravirion molecular therapies. J Hum Virol 3: 6±15.
Buehler C, Kim KH, Dong CY, Masters BR. 1999. Innovations in two-photon deep tissue micros-
copy. IEEE Eng Med Biol Mag 18: 23±30.
Bukrinsky M, Adzhubei A. 1999. Viral protein R of HIV-1. Rev Med Virol 9: 39±49.
Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-
Pazner S. 1998. Neutralization pro®les of primary human immunode®ciency virus type 1 isolates
in the context of coreceptor usage. J Virol 72: 6988±6996.
Chen BK, Feinberg MB, Baltimore D. 1997. The kappaB sites in the human immunode®ciency
virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for
viral growth. J Virol 71: 5495±5504.
Cohen GB, Rangan VS, Chen BK, Smith S, Baltimore D. 2000. The human thioesterase II protein
binds to a site on HIV-1 Nef critical for CD4 down-regulation. J Biol Chem 275: 23097±23105.
Cruz SS, Chapman S, Roberts AG, Roberts IM, Prior DA, Oparka KJ. 1996. Assembly and
movement of a plant virus carrying a green ¯uorescent protein overcoat. Proc Natl Acad Sci
USA 93: 6286±6290.
Da Poian AT, Gomes AM, Oliveira RJ, Silva JL. 1996. Migration of vesicular stomatitis virus
glycoprotein to the nucleus of infected cells. Proc Natl Acad Sci USA 93: 8268±8273.
Da Poian AT, Gomes AM, Coelho-Sampaio T. 1998. Kinetics of intracellular viral disassembly and
processing probed by Bodipy ¯uorescence dequenching. J Virol Methods 70: 45±58.
Deora A, Spearman P, Ratner L. 2000. The N-terminal matrix domain of HIV-1 Gag is su½-
cient but not necessary for viral protein U-mediated enhancement of particle release through a
membrane-targeting mechanism. Virology 269: 305±312.
